A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)
Status:
Completed
Trial end date:
2016-10-18
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to assess the ability of different Dupilumab dose
regimens, administered as monotherapy, to maintain the treatment response achieved after 16
weeks of initial treatment with Dupilumab monotherapy compared to placebo.